Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03473743
Title A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib Plus JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Metastatic or Surgically Unresectable Urothelial Cancer With Selected FGFR Gene Alterations
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications

transitional cell carcinoma

Therapies

Cetrelimab + Erdafitinib

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | BEL


No variant requirements are available.